Sunday, 11 May 2025
No Result
View All Result
eudebates.tv
  • EU Policies
  • World
  • Special Debates
  • Events
  • Vote & Polls
eudebates.tv
No Result
View All Result

EMA transparency and independence standards for treatments and vaccines

EUdebates Team by EUdebates Team
13/02/2021
in Health
Reading Time: 5 mins read
0
Exterior of European Medicines Agency in Amsterdam - EMA
134
SHARES
1.3k
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

Join EU debates

EU should debate mandatory vaccination, says Von der Leyen.

WHO: 115k health and care professionals died from pandemic

Vaccinated Europeans now outnumber those infected by COVID

Made in China vaccine gets WHO global approval for emergency use

The European Medicines Agency (EMA) has re-affirmed its long-standing commitment to independence and transparency in its evaluation of COVID-19 treatments and vaccines. Tried and tested measures ensure that EMA’s recommendations are driven only by science and public-health needs, and not by any other interests.

The scale of the COVID-19 public health crisis has led to unprecedented efforts by all those involved in the development of medicines to treat and prevent COVID-19, compressing a process that typically requires several years into one lasting only several months.

EMA and the national competent authorities have responded to these challenges by fully mobilising their resources to expedite their advice and evaluation processes, while maintaining their safety and efficacy standards and applying tested independence and EMA transparency rules. MEPs called for complete transparency regarding contracts and deployment of COVID-19 vaccines.

EMA transparency and OLAF controls

Maximum EMA transparency a pre-condition

EMA considers maximum transparency as a pre-condition for fostering trust and confidence in the EU regulatory system. It is also planning a range of additional measures to provide the public prompt insights into its development and safety-monitoring processes. This includes for example the publication of the product information with details of the conditions of use even before the formal marketing authorisation will be granted. Then follows the expedited publication of the full European Public Assessment Report (EPAR) and the publication of the risk management plans for authorised COVID-19 medicines in their entirety, rather than as a summary.

EU leaders see ‘dark red’ and urge Brussels and EMA to speed up vaccine delivery

In an PDF iconopen letter sent to European Ombudsman Emily O’Reilly in response to an enquiry on the role of EMA and its pandemic task force during the COVID-19 crisis, the Agency explains that it is applying the same independence measures to its experts dealing with COVID-19 treatments and vaccines as it does for those dealing with all medicines. This includes the experts involved in providing advice on these medicines’ development, as well as the experts evaluating them.

The letter also sets out the EMA transparency plans for COVID-19 treatments and vaccines. EMA will publish the clinical data underpinning its recommendations for all COVID-19 medicines. This falls under the scope of EMA’s landmark policy on proactive publication of clinical data, which the Agency is reinstating – exclusively for COVID-19 medicines at this point – following its suspension in August 2018 to allow the Agency to focus resources on its relocation from the United Kingdom to the Netherlands.

MEPs call for more clarity and transparency

Members of the European Parliament debate on the latest developments regarding contracts, transparency, authorisations, availability and deployment of COVID-19 vaccines. MEPs underlined the need for more clarity and transparency regarding vaccine contracts, as well as the decision-making process at EU level. They welcomed the European Commission’s openness to share available information whilst also acknowledging that some questions can be better answered by member states and pharmaceutical companies.

Many debate parliamentary questions concern possible additional national or bilateral contracts. The Commission confirms that it is not aware of any such alleged contracts. Through the Joint Procurement Agreement, the EU has priority to deliver vaccines, which will then be distributed to member states on a pro-rata basis.

Ursula von der Leyen admits to failings in vaccine EU plan

Many members emphasize that the EU had made the right key decisions, especially on the collective European approach to vaccination and on standing up for its citizens’ rights by putting safety first and enforcing EU liability rules.

In order to build citizens’ trust in the vaccination efforts and avoid disinformation, the EU must “tell the truth”, some MEPs pointed out. In this respect, many recalled the need for transparency with regard to contracts, as well as for comprehensive and clear data on vaccines rollout at national level.

“And yet it is a fact that we are not today where we want to be in the fight against the virus,” Ursula von der Leyen told EU lawmakers.

“We were late with the approval. We were too optimistic on mass production. And perhaps we were also too certain that the orders would actually be delivered on time,” she said.

Following requests from MEPs, the Commission provided information regarding a number of other specific issues:

  • A reading room is open for MEPs wishing to review vaccine contracts and agreements with pharmaceutical companies;
  • The largest quantities of vaccines will be during the second quarter of 2021, as already agreed in the existing contracts – specific strategies for deployment, including priority groups for vaccination, are set up by each member state;
  • A dedicated platform will be available where member states can report, twice a week, the number of vaccines received and used.

The European Medicines Agency (EMA) plays an important role in enabling the development, scientific evaluation, approval and monitoring of COVID-19 vaccines in the European Union (EU). Vaccines for COVID-19 are being developed, evaluated and approved according to current regulatory guidelines and legal requirements.

eudebates EMA transparency and independence

Share this debate with your friends!
Follow #eudebates on Google News and on Facebook
Tags: CoronavirusCOVIDCOVID19EU MEMBEREuropean Medicines Agency (EMA)European ParliamentMembers of the European ParliamentMEPTransparencyUrsula von der LeyenVaccinationVaccinationsVaccines
Share54Tweet34

Related EU debates

Ursula von der Leyen, President of the European Commission on the mandatory vaccination
Health

EU should debate mandatory vaccination, says Von der Leyen.

01/12/2021
Doctors mask virus health
Health

WHO: 115k health and care professionals died from pandemic

25/05/2021
A medical worker getting vaccinated against COVID-19 in Bulgaria
Health

Vaccinated Europeans now outnumber those infected by COVID

14/05/2021
Illustration picture of a vaccines - vaccine
Health

Made in China vaccine gets WHO global approval for emergency use

13/05/2021
small-baby mother newborn
Health

Health: Keep mothers and newborns together

16/04/2021
Stella Kyriakides, European Commissioner for Health and Food Safety
Health

World Health Day: Stella Kyriakides EU debates Health Union

06/04/2021

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SOTEU 2022 - State of the Union speech

Watch State of the Union live: Ursula von der Leyen gives 2022 address #SOTEU

14/09/2022
Volunteers preparing food for Ukrainian refugees arriving at Berlin Central Station

EU steps up solidarity with refugees fleeing Ukraine

08/03/2022
pump jack oil diesel

REPowerEU to get rid of the dependencies of Russian fossil fuel

08/03/2022
Ursula von der Leyen President of the European Commission

EU sanctions against Russia following the invasion of Ukraine

26/02/2022
Finnish PM Sanna Marin

Finland: NATO membership ‘will change’ after Russian invasion

24/02/2022
NATO - EU joint Press Conference

EU responds to Russia’s invasion of Ukraine with massive sanctions

24/02/2022
  • Social Media Facebook twitter

    DeleteFacebook? What is the best Facebook european alternative?

    268 shares
    Share 107 Tweet 67
  • Travelling in Europe with COVID19 country colour travel code zones

    238 shares
    Share 95 Tweet 60
  • Why don’t Mediterranean boat migrants take the plane? Why don’t refugees fly?

    222 shares
    Share 89 Tweet 56
  • EU nasty and vindictive? Nigel Farage criticizes EU vaccines strategy

    202 shares
    Share 81 Tweet 51
  • Burkini Debate: To Ban or Not to Ban the Burkini, Burka and Niqab in EUROPE?

    193 shares
    Share 77 Tweet 48

Join eudebates newsletter!

Enter your email to receive our newsletter.

Don't worry, we don't spam
eudebates_logo

Follow us on social media:

Recent News

  • Watch State of the Union live: Ursula von der Leyen gives 2022 address #SOTEU
  • EU steps up solidarity with refugees fleeing Ukraine
  • REPowerEU to get rid of the dependencies of Russian fossil fuel
  • EU sanctions against Russia following the invasion of Ukraine
  • Finland: NATO membership ‘will change’ after Russian invasion

Newsletter

Join eudebates newsletter!

Enter your email to receive our newsletter.

Don't worry, we don't spam
SOTEU 2022 - State of the Union speech

Watch State of the Union live: Ursula von der Leyen gives 2022 address #SOTEU

14/09/2022
Volunteers preparing food for Ukrainian refugees arriving at Berlin Central Station

EU steps up solidarity with refugees fleeing Ukraine

08/03/2022
pump jack oil diesel

REPowerEU to get rid of the dependencies of Russian fossil fuel

08/03/2022
  • Home
  • EU Policies
  • Special Debates
  • Events
  • Vote & Polls
  • Video

© 2022 eudebates - EU debates, dialogue, communication for a better Europe - Privacy Policy.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • EU Policies
  • World
  • Special Debates
  • Events
  • Vote & Polls

© 2022 eudebates - EU debates, dialogue, communication for a better Europe - Privacy Policy.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Visit our Privacy and Cookie Policy.